Ninth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast09 phase 3 trial results Thirteenth Breakthrough Therapy Designation granted ...

Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. A shopper pushes a cart past a display of soups in ...

The US economy shrank at a 0.5% annual pace from January through March as President Trump’s trade wars disrupted business, the Commerce Department reported Thursday in an unexpected deterioration of ...

Objectives: Rituximab (RTX) has been commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE), yet real-world data concerning RTX as the first-line ...

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with ...

The Department of Labor’s (DOL) 2023 reclassification of some H-2A workers’ job titles continues to push wages higher, with another increase on the way this year per the Bureau of Labor Statistics ...